Oura buys Counsel Health for $625 million to add AI-assisted doctors

Oura, the Finnish maker of the Oura smart ring, said on Tuesday, 10 November 2026 that it will buy Counsel Health, a US start-up that offers AI-assisted access to doctors, for $625 million in cash. The deal is expected to close before the end of 2026, subject to customary conditions and price adjustments. Counsel's service, which combines a medical chat assistant with licensed physicians, has run inside the Oura app since June. Alongside the deal, Oura reported that its revenue grew 153% year on year to $533 million in the quarter that ended on 30 September, according to reports.

Wearable devices like the Oura ring collect a constant stream of health data: how well a person sleeps, their resting heart rate, their temperature, how active they are. What they have lacked is a way to turn that data into medical care. A ring can tell a user their sleep has been poor for two weeks; it cannot prescribe treatment. By buying Counsel, Oura is trying to close that gap, so that a user who sees something worrying can chat with a doctor in the same app.

Counsel's model is what start-ups call "AI-native" care. An AI assistant handles the first conversation, collects symptoms and history, and drafts guidance, while licensed physicians step in when a medical decision is needed. The aim is to make a doctor's advice faster and cheaper to reach than a clinic visit. Oura's chief executive, Tom Hale, said the two companies together could create a new model of care. Not everyone is convinced; one health-technology commentator argued that offering access to physicians does not yet make Oura a health care provider.

The price is notable for a young company. Counsel raised $25 million in its Series A round a year ago, so a $625 million sale gives its investors a large return in a short time. For start-up founders and investors, it is a sign that AI health services with real users and a distribution partner can command high prices from companies that want to own the customer relationship.

For Indian readers, the deal is a reference point rather than a direct change: neither service has announced plans for India. But the question Oura is testing, whether a wearable company can become a health care company, is one Indian wearable and health-technology start-ups face too.

Peepals calculation: Oura's 153% growth to $533 million means the same quarter a year earlier brought in about $211 million (533 ÷ 2.53 ≈ 211). The $625 million price is about 1.2 times Oura's latest quarterly revenue (625 ÷ 533 ≈ 1.17) and 25 times the $25 million Counsel raised in its Series A (625 ÷ 25 = 25). Our calculation from the reported figures.

Short-term: Oura users already reach Counsel's doctors through the app; the deal brings that service in-house, and Counsel keeps its outside partners.

Long-term: If it works, wearables could become a front door to medical care, putting device makers in competition with telemedicine firms and clinics.

Who is affected: Oura ring users, Counsel Health's staff, partners and investors, telemedicine and wearable companies, and regulators who oversee digital medical services.

What to watch next: The deal's closing, which Oura expects before the end of 2026.

Questions and Answers